HUTCHMED (00013) completes vesting of 19,913 LTIP shares to CEO Dr Weiguo Su

Bulletin Express16:42

HUTCHMED (Stock Code: 00013) announced that 19,913 ordinary shares previously granted to Executive Director, Chief Executive Officer and Chief Scientific Officer Dr Weiguo Su under the company’s Long-Term Incentive Plan (LTIP) on 13 March 2024 fully vested on 13 March 2026.

The shares, carrying a par value of US$0.10 each and identified under ISIN KYG4672N1016, were awarded on a non-performance basis and vested at no consideration. The transaction was disclosed in line with the UK Market Abuse Regulation and Hong Kong Listing Rule 13.10B.

HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for cancer and immunological diseases. The company has three marketed medicines in China, with its lead product also approved in the US, Europe and Japan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198106460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198106460","market":"us","top_or_hot":-1,"title":"HUTCHMED (00013) completes vesting of 19,913 LTIP shares to CEO Dr Weiguo Su","media":"Bulletin Express","content":"<p>HUTCHMED (Stock Code: 00013) announced that 19,913 ordinary shares previously granted to Executive Director, Chief Executive Officer and Chief Scientific Officer Dr Weiguo Su under the company’s Long-Term Incentive Plan (LTIP) on 13 March 2024 fully vested on 13 March 2026.</p>\n<p>The shares, carrying a par value of US$0.10 each and identified under ISIN KYG4672N1016, were awarded on a non-performance basis and vested at no consideration. The transaction was disclosed in line with the UK Market Abuse Regulation and Hong Kong Listing Rule 13.10B.</p>\n<p>HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for cancer and immunological diseases. The company has three marketed medicines in China, with its lead product also approved in the US, Europe and Japan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED (00013) completes vesting of 19,913 LTIP shares to CEO Dr Weiguo Su</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (00013) completes vesting of 19,913 LTIP shares to CEO Dr Weiguo Su\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-16 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUTCHMED (Stock Code: 00013) announced that 19,913 ordinary shares previously granted to Executive Director, Chief Executive Officer and Chief Scientific Officer Dr Weiguo Su under the company’s Long-Term Incentive Plan (LTIP) on 13 March 2024 fully vested on 13 March 2026.</p>\n<p>The shares, carrying a par value of US$0.10 each and identified under ISIN KYG4672N1016, were awarded on a non-performance basis and vested at no consideration. The transaction was disclosed in line with the UK Market Abuse Regulation and Hong Kong Listing Rule 13.10B.</p>\n<p>HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for cancer and immunological diseases. The company has three marketed medicines in China, with its lead product also approved in the US, Europe and Japan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"","article_id":"1198106460","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198106460","pubTimestamp":1773650577,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"HUTCHMED (Stock Code: 00013) announced that 19,913 ordinary shares previously granted to Executive Director, Chief Executive Officer and Chief Scientific Officer Dr Weiguo Su under the company’s...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00013":"和黄医药"},"translate_title":"和黄医药(00013)完成向首席执行官苏卫国博士授予19,913股LTIP股份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1},"content_text":"HUTCHMED (Stock Code: 00013) announced that 19,913 ordinary shares previously granted to Executive Director, Chief Executive Officer and Chief Scientific Officer Dr Weiguo Su under the company’s Long-Term Incentive Plan (LTIP) on 13 March 2024 fully vested on 13 March 2026.\nThe shares, carrying a par value of US$0.10 each and identified under ISIN KYG4672N1016, were awarded on a non-performance basis and vested at no consideration. The transaction was disclosed in line with the UK Market Abuse Regulation and Hong Kong Listing Rule 13.10B.\nHUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for cancer and immunological diseases. The company has three marketed medicines in China, with its lead product also approved in the US, Europe and Japan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198106460","isCrawlerRequest":true}